<DOC>
	<DOCNO>NCT01549964</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 2 dos TAK-875 ( 25 mg 50 mg ) , daily ( QD ) , plus metformin compare placebo plus metformin sitagliptin plus metformin lowering blood sugar .</brief_summary>
	<brief_title>Comparison Fasiglifam ( TAK-875 ) Placebo Sitagliptin Combination With Metformin Participants With Type 2 Diabetes</brief_title>
	<detailed_description>TAK-875 develop Takeda Development Center , Inc. adjunct diet exercise improve glycemic control participant Type 2 Diabetes Mellitus ( T2DM ) whose blood glucose level inadequately control metformin . This study evaluate efficacy TAK-875 ( 25 mg 50 mg ) plus metformin compare placebo plus metformin sitagliptin plus metformin glycemic control measure change baseline glycosylated hemoglobin ( HbA1c ) 24-week Treatment Period . Participants complete 24-week Treatment Period may enter optional 80-week extension period total 104 week treatment . Due concern potential liver safety , balance , benefit treat patient fasiglifam ( TAK-875 ) outweigh potential risk . For reason , Takeda decide voluntarily terminate development activity fasiglifam .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . The participant male female 18 year age old historical diagnosis type II diabetes mellitus . 2 . The participant meet one follow criterion : 1 . The participant HbA1c level ≥7.5 &lt; 10.5 % , stable daily dose ≥1500 mg ( document maximum tolerate dose [ MTD ] ) metformin least 2 month prior Screening . This participant immediately enter Placebo Runin Period accord Study Schedule A , ; 2 . The participant HbA1c level ≥7.5 &lt; 10.5 % , stable daily dose &lt; 1500 mg metformin without document MTD least 2 month prior Screening . After complete Screening Visit , participant metformin dose immediately increased ≥1500 mg ( MTD ) 8week Titration Period accord Study Schedule B . Following 8week period , participant must qualify entry Placebo Runin Period complete Week 3 procedure include HbA1c level ≥7.5 &lt; 10.5 % . 3 . The participant treatment antidiabetic agent metformin within 2 month prior Screening ( Exception : participant receive antidiabetic therapy ≤7 day within 2 month prior Screening ) . 4 . The participant body mass index ( BMI ) ≤45 kg/m² Screening . 5 . Participants regularly use , nonexcluded medication , must stable dose least 4 week prior Screening . However , PRN ( need ) use prescription overthecounter medication allow discretion investigator . 6 . The participant able willing monitor glucose home glucose monitor consistently record blood glucose concentration complete subject diary . 1 . The participant donate receive blood product within 12 week prior Screening plan donate blood study . 2 . Hemoglobin ≤12 g/dL ( ≤120 g/L ) males ≤10 g/dL ( ≤100 g/L ) females Screening Visit . 3 . The participant systolic blood pressure ≥160 mm Hg diastolic pressure ≥95 mm Hg Screening Visit . ( If participant meet exclusion criterion , assessment may repeat least 30 minute initial measurement . ) 4 . The participant history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 5 . The participant treatment gastric band gastric bypass surgery within one year prior Screening . 6 . The participant coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal ECG , cerebrovascular accident transient ischemic attack within 3 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>